Abstract

BackgroundAcute cellular rejection (ACR) is associated with complications after kidney transplantation, such as graft dysfunction and graft loss. Early risk assessment is therefore critical for the improvement of transplantation outcomes. In this work, we retrospectively analyzed a pre-transplant HLA antigen bead assay data set that was acquired by the e:KID consortium as part of a systems medicine approach.ResultsThe data set included single antigen bead (SAB) reactivity profiles of 52 low-risk graft recipients (negative complement dependent cytotoxicity crossmatch, PRA < 30%) who showed detectable pre-transplant anti-HLA 1 antibodies. To assess whether the reactivity profiles provide a means for ACR risk assessment, we established a novel approach which differs from standard approaches in two aspects: the use of quantitative continuous data and the use of a multiparameter classification method. Remarkably, it achieved significant prediction of the 38 graft recipients who experienced ACR with a balanced accuracy of 82.7% (sensitivity = 76.5%, specificity = 88.9%).ConclusionsThe resultant classifier achieved one of the highest prediction accuracies in the literature for pre-transplant risk assessment of ACR. Importantly, it can facilitate risk assessment in non-sensitized patients who lack donor-specific antibodies. As the classifier is based on continuous data and includes weak signals, our results emphasize that not only strong but also weak binding interactions of antibodies and HLA 1 antigens contain predictive information.Trial registrationClinicalTrials.gov NCT00724022. Retrospectively registered July 2008.

Highlights

  • Acute cellular rejection (ACR) is associated with complications after kidney transplantation, such as graft dysfunction and graft loss

  • Pre-transplantation HLA-1 and HLA-2 Mixed HLA antigen bead (MAB) data were available for N = 63 recipients of the acute cellular rejection (ACR) group and N = 54 recipients of the control group

  • HLA-1 single HLA antigen bead (SAB) data was measured for all those patients who tested positive for HLA-1 MAB screening (21 ACR + 13 control) and a random subset of patients who tested negative (13 ACR + 5 control)

Read more

Summary

Introduction

Acute cellular rejection (ACR) is associated with complications after kidney transplantation, such as graft dysfunction and graft loss. Risk assessment is critical for the improvement of transplantation outcomes. The most common approach for pre-transplant risk assessment relies on the characterization of HLA antibodies in recipient serum samples by solid phase single HLA antigen bead (SAB) assay [24,25,26,27,28,29, 31]. The detection of DSA through SAB assays is a well-established method for antibody-mediated rejection (ABMR) pre-transplantation risk assessment, but not for ACR [24,25,26,27,28,29,30, 32]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call